Conclusion : The favourable effect of resveratrol emerging from the current meta- analysis suggests the possible use of this nutraceutical as active compound in order to promote cardiovascular health , mostly when used in high daily dose ( ≥300 mg/day ) and in diabetic patients
ABSTRACT Introduction : Results of previous clinical trials evaluating the effect of  resveratrol supplementation on blood pressure ( BP )  are controversial .
Purpose : We aim ed to assess the impact of resveratrol on BP through systematic review of literature and meta- analysis of available r and omized , controlled clinical trials ( RCTs ) .
Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial.
CONTEXT Metabolic syndrome ( MetS ) is associated with low- grade inflammation , which may harmfully affect bone . Resveratrol ( RSV ) possesses anti-inflammatory properties , and rodent studies suggest bone protective effects . OBJECTIVE This study sought to evaluate effects of RSV treatment on bone in men with MetS. SETTING AND DESIGN The study was conducted at Aarhus University Hospital as a r and omized , double-blinded , placebo-controlled trial assessing changes in bone turnover markers , bone mineral density ( BMD ) , and geometry . PARTICIPANTS The study population comprised 74 middle-aged obese men with MetS recruited from the general community , of which 66 completed all visits . Mean age of participants was 49.3 ± 6.3 years and mean body mass index was 33.7 ± 3.6 kg/m(2 ) . INTERVENTION Oral treatment with 1.000 mg RSV ( RSV(high ) ) , 150 mg RSV ( RSV(low ) ) , or placebo daily for 16 weeks . MAIN OUTCOME MEASURE Prespecified primary endpoint was change in bone alkaline phosphatase ( BAP ) . RESULTS BAP increased dose dependently with RSV ( R = 0.471 , P < .001 ) , result ing in a significantly greater increase in BAP in the RSV(high ) group compared with placebo at all time-points ( week 4 , 16.4 ± 4.2 % , P < .001 ; week 8 , 16.5 ± 4.1 % , P < .001 ; week 16 , 15.2 ± 3.7 % , P < .001 ) . Lumbar spine trabecular volumetric bone mineral density ( LS vBMD(trab ) ) also increased dose dependently with RSV ( R = 0.268 , P = .036 ) , with a significant increase of 2.6 ± 1.3 % in the RSV(high ) group compared with placebo ( P = .043 ) . In addition , changes in BAP and LS vBMD(trab ) were positively correlated ( R = 0.281 , P = .027 ) . No consistent changes were detected in bone density at the hip . CONCLUSIONS Our data suggest that high-dose RSV supplementation positively affects bone , primarily by stimulating formation or mineralization . Future studies of longer duration comprising population s at risk of osteoporosis are needed to confirm these results
Conclusion : The favourable effect of resveratrol emerging from the current meta- analysis suggests the possible use of this nutraceutical as active compound in order to promote cardiovascular health , mostly when used in high daily dose ( ≥300 mg/day ) and in diabetic patients
ABSTRACT Introduction : Results of previous clinical trials evaluating the effect of  resveratrol supplementation on blood pressure ( BP )  are controversial .
Purpose : We aim ed to assess the impact of resveratrol on BP through systematic review of literature and meta- analysis of available r and omized , controlled clinical trials ( RCTs ) .